TrialNature medicine2022

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.

Andrew Feigin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.